Sai Life Sciences becomes a signatory of the United Nations Global Compact (UNGC)

HYDERABAD, India, Aug. 26, 2021 /PRNewswire/ -- Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), today announced that it has become a signatory of the United Nations Global Compact (UNGC), the world's largest sustainability initiative. As a signatory, Sai Life Sciences has committed itself to adopting the Ten Principles of the UNGC on human rights, labour, environment and anti-corruption, reinforcing the company's commitment to corporate responsibility and sustainability.

 

Making the announcement, Krishna Kanumuri, CEO & Managing Director said, "As we pursue our vision and business growth, we consciously integrate our social, environmental and governance responsibilities. We have committed ourselves to implement Ten Principles of the UNGC and to make them part of the strategy, culture and day-to-day operations of our company. This will help us in strengthening our sustainability agenda and also accelerate our progress towards achieving our Sustainable Development Goals (SDGs)."

Over the past two years, Sai Life Sciences has made significant investments and progress in advancing its Sustainability agenda as part of its organizational transformation initiative, Sai Nxt. Some of the notable highlights:

• Became the first India-headquartered company to join the PSCI membership.
• Joined ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS-GCIPR) as an 'Associate Member'.
• Released its first Sustainability Report in 2020 in line with the GRI framework
• Received the ISO 14001:2015 and ISO 45001:2018 certifications for its R&D and manufacturing sites.
• Won the prestigious 21st National Award for Excellence in Energy Management 2020 by CII - Sohrabji Godrej Green Business Centre
• Received 5-Star rating for Excellence in EHS Practices at the Confederation of Indian Industry (CII) South awards 2019 and 2020.

About Sai Life Sciences

Sai Life Sciences is a full-service CRO-CDMO that works with innovator pharma and biotech companies globally, to accelerate the discovery, development and commercialisation of complex small molecules. For over two decades, Sai Life Sciences has consistently delivered high-quality, cost-effective solutions to its diverse customers spanning biotechs, small, mid and large pharma. Today, it has over 2200 employees across its facilities in India, UK and USA. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com.

Sai Life Sciences releases its first Sustainability Report

Developed as per the Global Reporting Initiative (GRI) standards 

Highlights the various sustainable choices embraced by the company in steering its journey on a sustainable path

HYDERABAD, India, Dec. 14, 2020 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing Contract Research, Development & Manufacturing Organizations (CRO/ CDMO), today announced the release of its first Sustainability Report as per the Global Reporting Initiative (GRI) standards. The report sheds light on the company's progress during 2019-20 across the three pillars of sustainability i.e. economic, environment and social.  

Making the announcement, Krishna Kanumuri, CEO & Managing Director said, "I am delighted to present our inaugural, 2019-2020 Sustainability Report. It reflects our deep commitment towards sustainability, in our pursuit of bringing new medicines to life. It also is a reaffirmation of our promise to Make it better together with all stakeholders, which functions as a key driver in continuously refining our sustainability practices and achieving business growth responsibly."

The report highlights the company's progress on all issues that are critical for its business and stakeholders. It details the various initiatives driving the company's progress towards its stated sustainable development goals. During the year, Sai Life Sciences surpassed its goals for the responsible disposal of hazardous waste and its community outreach programs. It also is steadily progressing towards utilizing renewable power to meet its energy needs. It instituted the 'Green Chemistry Awards' to celebrate and recognize teams that demonstrate discernible improvements over established processes. The full report can be accessed here.

Speaking on the occasion, Sreekrishna Chopperla, Vice President & Head – Corporate Health, Safety & Environment said, "Over time, we have been able to inculcate in our employees an innate mindset towards sustainability. This enables our progress towards the sustainability development goals each day. We will continue to follow this path as we expand and grow, keeping sustainable development at the core."

The release of the 2020 Sustainability Report caps a highly productive year for Sai Life Sciences from a sustainability perspective. Some of the highlights:

• Became the first India-headquartered company to join the PSCI membership.
• Received the ISO 14001:2015 and ISO 45001:2018 certifications for its R&D facility, manufacturing site and corporate office. 
• Joined ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS-GCIPR) as an 'Associate Member'. 
• Won the prestigious 21st National Award for Excellence in Energy Management 2020 by CII - Sohrabji Godrej Green Business Centre 
• Received 5-Star rating for Excellence in EHS Practices at the Confederation of Indian Industry (CII) South awards 2019. 

Further, through its proactive response to the COVID-19 pandemic, the company ensured minimal impact on its stakeholders and business operations by safeguarding workforce, ensuring business continuity with its supplier and customers, and supporting the community.

About Sai Life Sciences

Sai Life Sciences is a full-service CRO/ CDMO driven by a vision to support the launch of 25 new medicines by 2025. It works with innovator pharma and biotech companies globally, accelerating the discovery, development and manufacture of complex small molecules. As a pure-play services company, Sai Life Sciences has served a diverse set of NCE development programs, consistently delivering value based on its quality and responsiveness. Today, it works with 7 of the top 10 large pharma companies, as well as several small and mid-sized pharma & biotech companies. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com

Sai Life Sciences Opens New, State-of-the-Art Research & Technology Centre in Hyderabad

• Completes first phase in committed investment of US$ 150M (> INR 1000 Cr)


• Sri KT Rama Rao, Hon'ble Minister for Industry & Commerce and IT, Government of Telangana inaugurates the facility

Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the inauguration of its new Research and Technology (R&T) Centre in Hyderabad, India. Sri K T Rama Rao, Hon'ble Minister for Industry & Commerce and IT, Government of Telangana formally inaugurated the facility in the presence of other dignitaries.

Speaking on the occasion, Sri KT Rama Rao said, "I'm very happy that the esteemed leadership of Sai Life sciences has considered Telangana for setting up their new R&D centre. Life Sciences is one of the key focus sectors for the Government of Telangana. Hyderabad serves more than 1000 global innovators in their vision to develop innovative and affordable medicines for the world. I sincerely congratulate the entire team of Sai Life Sciences, not only for the new Research & Technology Centre but, also for their work towards the development and manufacturing of new life saving medicines."

[caption id="" align="aligncenter" width="400"] Inauguration of Sai Life Sciences’ New Research & Technology Centre. Seen in the picture from left to right – Krishna Kanumuri, CEO & MD Sai Life Sciences, Sri K T Rama Rao, Hon'ble Minister for IT, Industries, MA & UD and Jayesh Ranjan, Principal Secretary to Government Industries and Commerce (PRNewsfoto/Sai Life Sciences)[/caption]

Built with an aspiration to achieve the best global benchmarks in lab infrastructure, the new R&T facility has several unique aspects such as intelligent & ergonomic lab design to enhance safety and productivity, advanced automation for seamless data capture during process development, lean & 5S approach to enhance productivity and collaborative workspaces for engendering innovation.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences said, "Our philosophy behind building this new facility was to go beyond what the norm is in India and to create what our global innovator partners expect in their inhouse capabilities." He further added, "We are an example of what is possible in Hyderabad's rich life sciences ecosystem. Today, as we build world class R&D capabilities and invest in nurturing talent with deep domain expertise, I can unhesitatingly say, Hyderabad is truly a city where pharma dreams are made."

The new 83,000 sq.ft. (7700 sq.m.) facility houses state-of-the-art research capabilities and advanced technology platforms, augmenting the company's capabilities in providing superior scientific solutions to its pharma and biotech innovator customers globally. It has 24 chemistry labs with 250 fume hoods, analytical labs, fully equipped technology suite and a dedicated process safety lab.

Sai Life Sciences began a process of organizational transformation in 2019 reinventing itself as a new generation global CDMO. Through this initiative, named Sai Nxt, the company is investing over US$ 150M (> INR 1000 Cr) to expand and upgrade its R&D and manufacturing facilities, induct top-notch global scientific and leadership talent, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

About Sai Life Sciences
Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines by 2025.  It works with innovator pharma and biotech companies globally, accelerating the discovery, development and manufacture of complex small molecules. A pure-play CDMO, Sai Life Sciences has served a diverse set of NCE development programs, consistently delivering value based on its quality and responsiveness. Today, it works with 7 of the top 10 large pharma companies, as well as several small and mid-sized pharma & biotech companies. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com/

 

,